Confronting a bird flu outbreak in nature presents unique challenges, as infected animals leave a landscape contaminated, Pa.

(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

UK contract research organization hVIVO (AIM: HVO) is gearing up to test an inhaled antiviral candidate, IN-002, for ...

Inhalon Biopharma, Inc. (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections (ARI), today announced the completion of ...